FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. (FBLG) announced that on May 4, 2026 the Compensation Committee granted stock options under the Company’s 2022 Stock Plan to four senior executives. CEO Pete O’Heeron received options to purchase 92,410 shares; CFO Jason D. Davis, CSO Hamid Khoja, Ph.D., and General Counsel Ruben A. Garcia each received options to purchase 61,607 shares. The options have an exercise price of $1.38 per share.

Key Details

• Grant date: May 4, 2026; 8-K filed May 5, 2026 and signed by CEO Pete O’Heeron.
• Option counts: 92,410 (CEO) and 61,607 each (three other officers); total granted = 277,231 options.
• Exercise price: $1.38 per share.
• Vesting: 25% vests on the one-year anniversary of the grant; remaining 75% vests in 36 equal monthly installments thereafter, subject to continuous service.

Why It Matters
These grants align senior management compensation with company performance and retention through multi-year vesting. If exercised, the options would increase the company’s outstanding common stock (potential dilution). Investors should note the size, exercise price and multi-year vesting schedule when assessing executive incentives and potential future dilution.